Short answer
Biogen (BIIB) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Biogen reported second-quarter results for the period ended June 30, 2026.
Biogen 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Biogen reported second-quarter results for the period ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the operating and financial results
- Results disclosure is furnished under Item 2.02 and does not constitute a filing for liability purposes
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $2.736B, up 3% YoY, led by Growth Portfolio revenue of $1.06B, up 24%
- Non-GAAP EPS $3.60 versus $5.47, pressured by acquisition costs, pipeline investment, and Apellis financing expense
- Apellis contribution: SYFOVRE $97M and EMPAVELI $30M recognized post-close, with expected 2026 EPS dilution of $0.85
- FY2026 reported Non-GAAP EPS guidance cut to $12.00–$13.00 despite underlying guidance rising $0.60 to $15.85–$16.85
- Balance-sheet leverage increased to $8.1B debt and $6.8B net debt; Apellis expected accretive in 2027 with at least $250M run-rate synergies exiting 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biogen 8-K filings
Get the next BIIB 8-K as it lands
Follow BIIB for push alerts, or ask the research agent what this filing means.